Completed PHASE1 INTERVENTIONAL 2-arm NCT00599001

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Male Volunteers

Sponsor: Dynavax Technologies Corporation

Conditions Healthy

Interventions SD-101 placebo

Updated 9 times since 2017 Last updated: Apr 11, 2019 Started: Jan 31, 2008 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Dynavax Technologies Corporation leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
May 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Mar 2019 — May 2019 [monthly]

Completed PHASE1
Jun 2018 — Mar 2019 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dynavax Technologies Corporation

Data source: Dynavax Technologies Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States